|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
Private Placement
On April 7, 2020, Idera Pharmaceuticals, Inc. (the “Company”)
entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Pillar Partners Foundation,
L.P. (the “Purchaser”), providing for a private placement transaction (the “Transaction”) exempt from the
registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company
has issued and sold, for $5.0 million of aggregate consideration (the “First Closing”), (i) 3,039,514 shares (the “First
Closing Shares”) of the Company’s common stock, par value 0.001 (the "Common Stock") and (ii) warrants to
purchase 3,039,514 shares of Common Stock (the “First Closing Common Warrants”). Each First Closing Share and the associated
First Closing Common Warrant had a combined purchase price of $1.645. Each combined purchase price included $0.125 for each share
of Common Stock underlying each First Closing Common Warrant. The First Closing Common Warrants have an exercise price of $2.28
per share of Common Stock.
Pursuant to the Securities Purchase Agreement, the Company has
also agreed to issue and sell to the Purchaser, for $5.0 million of aggregate consideration (the “Second Closing”),
(i) 2,747,252 shares of Common Stock (the “Second Closing Shares” and, together with the First Closing Shares, the
“Shares”) (or pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu
of certain Second Closing Shares to the extent that purchasing such second Closing Shares will cause the Purchaser to beneficially
own in excess of 19.99% of the total number of shares of Common Stock outstanding post transaction), and (ii) warrants to purchase
up to 1,373,626 shares of Common Stock (the “Second Closing Common Warrants” and, together with the First Closing Common
Warrants, the “Common Warrants”). Each Second Closing Share and the associated 0.5 Second Closing Common Warrant will
have a combined purchase price of $1.82 and each Pre-Funded Warrant and the 0.5 associated Second Closing Common Warrant will have
a combined purchase price of $1.81. Each combined purchase price includes $0.125 for each share of Common Stock underlying each
Second Closing Common Warrant. The Second Closing will occur on or before December 30, 2020 and will be held on or before the fifth
day following delivery of written notice by the Purchaser to the Company; provided, however, that if at any time after June
30, 2020, the Company’s Common Stock has achieved a closing price on the principal trading market of at least $3.01 per share
for twenty (20) consecutive trading days, the Company may elect, in its sole discretion, to cancel the Second Closing.
The Pre-Funded Warrants issuable pursuant to the Securities
Purchase Agreement have an exercise price of $0.01 per share of Common Stock and will be immediately exercisable upon issuance,
provided that the Purchaser will be prohibited, subject to certain exceptions, from exercising a Pre-Funded Warrant for shares
of Common Stock to the extent that immediately prior to or after giving effect to such exercise, the Purchaser, together with its
affiliates and other attribution parties, would own more than 19.99% of the total number of shares of Common Stock then issued
and outstanding (the “Beneficial Ownership Limitation”), which percentage may be changed at the Purchaser’s election
to a lower percentage at any time or to a higher percentage not to exceed 19.99% upon 61 days’ notice to the Company. The
Pre-Funded Warrants do not have an expiration date.
The Common Warrants are exercisable at any time or times on
or after the next business day after the date on which the Company publicly announces through the filing of a Current Report on
Form 8-K that an amendment to the Company Restated Certificate of Incorporation, as amended, to sufficiently increase the Company’s
authorized shares of Common Stock to cover the exercise of the Common Warrants into Common Stock has been filed with the Secretary
of State of the State of Delaware, provided that the Purchaser will be prohibited, subject to certain exceptions, from exercising
a Common Warrant for shares of Common Stock to the extent that the Purchaser would beneficially own in excess of the Beneficial
Ownership Limitation, which percentage may be changed at the holder’s election to a lower percentage at any time or to a
higher percentage not to exceed 19.99% upon 61 days’ notice to the Company. The Common Warrants will expire three years from
the date of issuance.
The securities issued and sold in connection with the Transaction
are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act. The Purchaser is either
(i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities
Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.
Concurrently with the execution of the Securities Purchase
Agreement, the Company entered into a voting agreement (the “Voting Agreement”) with the Purchaser, pursuant to
which the Purchaser agreed, in any annual, special or adjourned meeting of the shareholders of the Company at which the
Company seeks approval of the stockholders of the Company to increase the authorized shares of Common Stock (or to effect a
reverse split of the Common Stock) in an amount sufficient to cover the exercise of the Common Warrants (the “Required
Shareholder Approval”), that it will vote, by proxy or otherwise, all of its shares of voting capital stock of the
Company (i) in favor of such matter and any matter that would reasonably be expected to facilitate such Required Shareholder
Approval, and (ii) against approval of any proposal made in opposition to such matters. The Voting Agreement will terminate
upon the earliest to occur of (i) the date on which the Company receives the Required Shareholder Approval, (ii) the
termination of the Securities Purchase Agreement in accordance with its terms and (iii) April 7, 2021.
In addition, concurrently with the execution of the Securities
Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”)
with the Purchaser, pursuant to which the Company agreed, following demand by the Purchaser to file with the Securities and Exchange
Commission a Registration Statement on Form S-3 covering the resale of all of the Registrable Securities as promptly as reasonably
practicable following such demand, and in any event within 60 days of such demand.
The foregoing descriptions of the Securities Purchase Agreement,
Voting Agreement, Registration Rights Agreement and the form of the Pre-Funded Warrant and the Common Warrant do not purport to
be complete and are qualified in their entirety by reference to the full text of such agreements, filed herewith as Exhibits 10.1,
4.3.,4.4, 4.1 and 4.2 and are incorporated herein by reference.